Mdb Capital Holdings, LLC

MDB Capital Holdings, LLC announced the appointment of seasoned investor Jeb Terry Sr. as an independent director and the retirement of long-serving director Susanne Meline.

MDB Capital Holdings' shareholders elected seven directors and ratified RBSM LLP as its independent auditor at the 2025 Annual Meeting.

MDB Capital Holdings, LLC announced key leadership transitions within its Board of Directors, with Matthew Hayden stepping down to assume a new strategic role as Entrepreneur in Residence and Dan Torpey appointed as Audit Committee Chair.

MDB Capital Holdings' senior executives have agreed in principle to surrender 3,600,000 restricted stock units in exchange for new stock options.

MDB Capital Holdings held its 2024 Annual Meeting, electing eight directors, approving executive compensation, and ratifying its auditor.

MDB Capital Holdings has funded a new entity, MDB Minnesota One, and secured a license from the Mayo Foundation to develop a small molecule senescence platform.

MDB Capital Holdings, LLC reported a net loss for Q3 2025, with total assets and equity decreasing significantly, while actively addressing material weaknesses in internal controls and navigating strategic shifts in its technology development segment.

MDB Capital Holdings, LLC reported a significantly increased net loss for the second quarter and first half of 2025, driven by unrealized investment losses and a new equity loss from its deconsolidated eXoZymes subsidiary, alongside identified material weaknesses in internal controls.

MDB Capital Holdings' Q1 2025 results reveal a net loss driven by unrealized investment losses and the adoption of equity method accounting for eXoZymes after its IPO.

MDB Capital Holdings reported a net loss of $8.4 million for the third quarter of 2024, driven by increased operating costs and unrealized losses on investment securities.

MDB Capital Holdings reported a net loss for the second quarter of 2024, driven by decreased fee income and increased operating expenses, despite gains in investment securities.

MDB Capital Holdings reported a net loss of $7.6 million for the first quarter of 2024, driven by unrealized losses on investment securities and increased operating costs.

MDB Capital Holdings reports a significant net loss for 2025, driven by deconsolidation of eXoZymes and increased equity method losses, despite growth in investment banking fees.

MDB Capital Holdings reports its FY2024 financial results, highlighting the deconsolidation of eXoZymes, strategic shifts in operations, and ongoing efforts to strengthen internal controls.

MDB Capital Holdings' 10-K filing details its authorized capital, governance structure, and the rights of its Class A and Class B common shareholders.

Director Daniel Torpey acquired 20,000 shares of MDB Capital Holdings, LLC common stock through the conversion of restricted stock units.

Director Daniel Thomas Torpey was granted 100,000 restricted stock units in MDB Capital Holdings, LLC.

Co-Founder Christopher A. Marlett was granted 100,000 employee stock options in MDB Capital Holdings, LLC.

MDB Capital Holdings, LLC CFO, James Jeremy William, acquired 10,000 shares of common stock on February 9, 2026, at a price of $3.90 per share.

Director Daniel Thomas Torpey reported the acquisition of 10,000 shares of MDB Capital Holdings, LLC (MDBH) common stock on April 20, 2026.

Director Sean Magennis reported a transaction involving 10,000 shares of MDB Capital Holdings, LLC common stock.

MDB Capital Holdings, LLC announces its 2025 Annual Meeting of Shareholders to be held virtually on December 2, 2025, to elect directors and ratify its independent accounting firm.

MDB Capital Holdings announces its 2024 annual shareholder meeting to be held virtually on December 10, 2024, featuring proposals for director elections, executive compensation, and auditor ratification.